Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 601–700 of 1,024
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Palomba, M. L., Halton, E. F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122627 · Cited by 107
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Schaft, N. (2020) · Cancers · doi:10.3390/cancers12092567 · Cited by 99
“efficacy and very long persistence of 4-1BB-containing CAR-T cells in patients were also reported in clinical trials [4,130].”
BackgroundCAR-T cells: Early successes in blood cancer and challenges in solid tumors
Dana, H., Chalbatani, G. M., Jalali, S. A., Mirzaei, H. R., Grupp, S. A., Suarez, E. R., Rapôso, C., & Webster, T. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.020 · Cited by 108
Self-citationNeurological updates: neurological complications of CAR-T therapy
Tallantyre, E. C., Evans, N. A., Parry-Jones, J., Morgan, M. P. G., Jones, C. H., & Ingram, W. A. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10237-3 · Cited by 105
Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 115
Goodman, D. B., Azimi, C. S., Kearns, K., Talbot, A., Garakani, K., Garcia, J. M., Patel, N. A., Hwang, B., Lee, D. S., Park, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm1463 · Cited by 113
CAR-NK cell therapy: promise and challenges in solid tumors
Balkhi, S., Zuccolotto, G., Spirito, A. D., Rosato, A., & Mortara, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574742 · Cited by 109
Imaging of T-cells and their responses during anti-cancer immunotherapy
Krekorian, M., Fruhwirth, G. O., Srinivas, M., Figdor, C. G., Heskamp, S., Witney, T. H., & Aarntzen, E. H. J. G. (2019) · Theranostics · doi:10.7150/thno.37924 · Cited by 106
“Infrastructures for centralised manufacturing and recent clinical trials have accelerated approval of the first CAR T-cell products for B-cell lymphoma and B-cell acute lymphoblastic leukaemia [10-12].”
Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad
Bleve, A., Durante, B., Sica, A., & Consonni, F. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165845 · Cited by 111
“Currently, two CD19-targeting CAR T cell therapies are approved for clinical use by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for diffuse large B cell lymphoma [84,85].”
BackgroundKong, W., Dimitri, A. J., Wenliang, W., Jung, I.-Y., Ott, C. J., Fasolino, M., Wang, Y., Kulikovskaya, I. M., Gupta, M., Yoder, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145459 · Cited by 103
Self-citationKim, M. Y., Jayasinghe, R. G., Devenport, J. M., Ritchey, J., Rettig, M. P., O’Neal, J., Staser, K. W., Kennerly, K., Carter, A. J., Gao, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30860-0 · Cited by 104
Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 105
Self-citationThe Next Phase of Human Gene-Therapy Oversight
Collins, F. S., & Gottlieb, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1810628 · Cited by 96
Quintarelli, C., Sivori, S., Caruso, S., Carlomagno, S., Falco, M., Boffa, I., Orlando, D., Guercio, M., Abbaszadeh, Z., Sinibaldi, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0613-7 · Cited by 101
Infectious complications of CAR T-cell therapy: a clinical update
Stewart, A. G., & Henden, A. S. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211036773 · Cited by 111
“41 Idecabtagene vicleucel 54 R/R multiple myeloma All 12 months 13/54 (24) 15/54 (28) 4/54 (7)”
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
Mehta, P. H., Fiorenza, S., Koldej, R. M., Jaworowski, A., Ritchie, D. S., & Quinn, K. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780442 · Cited by 95
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Viaud, S., Ma, J. S. Y., Hardy, I. R., Hampton, E. N., Benish, B., Sherwood, L., Núñez, V., Ackerman, C. J., Khialeeva, E., Weglarz, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810060115 · Cited by 105
“We developed a syngeneic murine-based switchable CAR T cell platform with murine 4–1BB-based second- and third-generation costimulatory domains that match the human homologs used clinically to promote persistence (1, 10, 21).”
BackgroundMethodCsizmar, C. M., Petersburg, J. R., Perry, T. J., Rozumalski, L., Hackel, B. J., & Wagner, C. R. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b09198 · Cited by 102
“After two weeks, when tumors had grown to 8–12 mm in diameter, mice were randomly assigned to one of five groups (n = 3 mice/group): (1) 0:8 T:NT CSANs; (2) 8:0 C5:NT CSANs; (3) 4:4 C5:NT CSANs; (4) 8:0 B22:NT CSANs; and (5) 4:4 B22:NT CSANs.”
MethodImmunotherapies for the Treatment of Uveal Melanoma—History and Future
Schank, T. E., & Hassel, J. C. (2019) · Cancers · doi:10.3390/cancers11081048 · Cited by 97
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Yu, B., & Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0786-6 · Cited by 101
Laetsch, T. W., Myers, G. D., Baruchel, A., Dietz, A. C., Pulsipher, M. A., Bittencourt, H. N. D. S., Buechner, J., Moerloose, B. D., Davis, K. L., Nemecek, E. R., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30493-0 · Cited by 98
Self-citationCAR-T cell therapy: a potential new strategy against prostate cancer
Schepisi, G., Cursano, M. C., Casadei, C., Menna, C., Altavilla, A., Lolli, C., Cerchione, C., Paganelli, G., Santini, D., Tonini, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0741-7 · Cited by 99
Xie, B., Li, Z., Zhou, J., & Wang, W. (2022) · Cancers · doi:10.3390/cancers14133230 · Cited by 103
“For example, OS for ALL patients treated with CD19 Si-CAR T cells [3,30] was close to those with CD22 Si-CAR T cells [62], which was shorter than those treated with CD19/CD22 Bi-CART cells [30].”
BackgroundResultInfluentialSilveira, C. R. F., Corveloni, A. C., Caruso, S. R., Macêdo, N. A., Brussolo, N. M., Haddad, F., Fernandes, T. R., de Andrade, P. V., Orellana, M. D., & Cunha, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947648 · Cited by 106
Bexte, T., Albinger, N., Al-Ajami, A., Wendel, P., Buchinger, L., Geßner, A., Alzubi, J., Särchen, V., Vogler, M., Rasheed, H. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52388-1 · Cited by 106
Determinants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 107
Autologous CAR T-cell therapies supply chain: challenges and opportunities?
Papathanasiou, M. M., Stamatis, C., Lakelin, M., Farid, S. S., Titchener-Hooker, N. J., & Shah, N. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-019-0157-z · Cited by 110
Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy
Li, C., Mei, H., & Hu, Y. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz042 · Cited by 104
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00262 · Cited by 101
Applying a clinical lens to animal models of CAR-T cell therapies
Duncan, B. B., Dunbar, C. E., & Ishii, K. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.008 · Cited by 106
Ghorashian, S., Lucchini, G., Richardson, R., Nguyen, K., Terris, C., Guvenel, A., Espuelas, M. O., Yeung, J., Pinner, D., Chu, J., et al. (2023) · Blood · doi:10.1182/blood.2023020621 · Cited by 106
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 105
“…and non-Hodgkin lymphoma (NHL), 50% and 56% of patients, respectively, experienced relapse from CAR-T cell treatment at 12-month follow-up [4, 5], and a cell therapy remains to be approved for chronic lymphocytic leukemia (CLL), where only 26% of patients present with a durable response [6].”
BackgroundCurrent and future immunotherapy for breast cancer
Heater, N. K., Warrior, S., & Lu, J. M. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01649-z · Cited by 115
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 118
Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function
Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1319 · Cited by 95
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Smith, E. L., Mailankody, S., Stæhr, M., Wang, X., Sénéchal, B., Purdon, T. J., Daniyan, A. F., Geyer, M. B., Goldberg, A. D., Mead, E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0551 · Cited by 97
“CAR T-cell therapy targeting CD19 has shown efficacy for the treatment of relapsed/refractory adult and pediatric B-cell acute lymphoblastic leukemia (11, 12) and large B-cell lymphomas (13).”
BackgroundThe Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology
Mohseni, Y. R., Tung, S. L., Dudreuilh, C., Lechler, R. I., Fruhwirth, G. O., & Lombardi, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01608 · Cited by 98
Immunotherapy for advanced hepatocellular carcinoma, where are we?
Li, Z., Ding, J., Li, H., Wang, Z., & Wu, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188441 · Cited by 101
Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
Pan, J., Deng, B., Ling, Z., Song, W., Xu, J., Duan, J., Wang, Z., Chang, A. H., Feng, X., & Tan, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16176 · Cited by 101
“The previous times of treatments were 30 (7-72) months.”
BackgroundYu, L., Huang, L., Lin, D., Lai, X., Wu, L., Liao, X., Liu, J., Zeng, Y., Liang, L., Zhang, G., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03839-5 · Cited by 102
Oncologic emergencies and urgencies: A comprehensive review
Rothberg, B. E. G., Quest, T. E., Yeung, S. J., Pelosof, L. C., Gerber, D. E., Seltzer, J. A., Bischof, J. J., Thomas, C. R., Akhter, N., Mamtani, M., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21727 · Cited by 139
Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Choi, G., Shin, G., & Bae, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912366 · Cited by 110
“CRS is a systemic inflammatory response observed after adoptive T-cell therapy [25].”
BackgroundMethodInfluentialTumor microenvironment and immunotherapy for triple-negative breast cancer
Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00714-6 · Cited by 102
How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia
Ravandi, F. (2018) · Blood · doi:10.1182/blood-2018-08-832105 · Cited by 96
Engineering advanced cancer therapies with synthetic biology
Wu, M.-R., Jusiak, B., & Lu, T. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0121-0 · Cited by 114
Rice, J., Nagle, S. J., Randall, J., & Hinson, H. E. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0580-3 · Cited by 98
Bo, M. D., Mattia, E. D., Baboçi, L., Mezzalira, S., Cecchin, E., Assaraf, Y. G., & Toffoli, G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100702 · Cited by 103
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 101
“Cancer Immunol Res (2019) 7(2):219–29.”
BackgroundInfluentialCombining chemotherapy with CAR-T cell therapy in treating solid tumors
Wang, A. X., Ong, X., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140541 · Cited by 113
“a maximum of 105 days (median time of 45 days) in the ELIANA trial (NCT02435849) (3).”
BackgroundStelljes, M., Raffel, S., Alakel, N., Wäsch, R., Kondakci, M., Scholl, S., Rank, A., Hänel, M., Spriewald, B. M., Hanoun, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00546 · Cited by 94
“20 Additional targeted and immune cell – based approaches in B-ALL treatment, including the CD19/CD3 bispeci fi c antibody construct blinatumomab 8,12 as well as chimeric antigen receptor T-cell products targeting CD19 21,22 and CD22, 23 have demonstrated high, but often short-lived, activity in r/r B-ALL.”
BackgroundHypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments
Feldman, L. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384249 · Cited by 103
Pinto, E., Lione, L., Compagnone, M., Paccagnella, M., Salvatori, E., Greco, M., Frezza, V., Marra, E., Aurisicchio, L., Roscilli, G., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06052-3 · Cited by 100
Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes
Frank, A. M., & Buchholz, C. J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.006 · Cited by 97
“Food and Drug Administration (FDA) and the European Medicines Agency (EMA).(9,10) Efforts are being put into improving the CAR technology to increase safety and efficacy, reduce production costs, and make it applicable beyond hematological malignancies.”
BackgroundA highly soluble Sleeping Beauty transposase improves control of gene insertion
Querques, I., Mades, A., Zuliani, C., Miskey, C., Alb, M., Grueso, E., Machwirth, M., Rausch, T., Einsele, H., Ivics, Z., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0291-z · Cited by 92
Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells
Ashmore‐Harris, C., Iafrate, M., Saleem, A., & Fruhwirth, G. O. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.016 · Cited by 98
“While new vectors inherently trigger safety evaluations and thus are expensive to develop, there has still been significant progress in this domain in recent years,(232,233) with ready-touse platforms for clinical use available.(7,12) Crucially, reporter genes must be co-delivered either in the same or a separate vect…”
BackgroundMyburgh, R., Kiefer, J. D., Russkamp, N. F., Magnani, C. F., Núñez, N. G., Simonis, A., Pfister, S., Wilk, C. M., McHugh, D., Friemel, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0818-9 · Cited by 98
Yan, Z., Zhang, H.-X., Cao, J., Zhang, C., Liu, H., Huang, H., Cheng, H., Qiao, J., Wang, Y., Wang, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611366 · Cited by 102
“CRS is one of the adverse events with high incidence in CAR-T cell treatment (4).”
BackgroundGoydel, R. S., & Rader, C. M. (2021) · Oncogene · doi:10.1038/s41388-021-01811-8 · Cited by 97
“Notably, simultaneously with the FDA approval of the first CAR-T, tisagenlecleucel (Kymriah), in 2017, the anti-IL6 receptor mAb tocilizumab (Actemra) received FDA approval for CAR-T-induced CRS [35].”
BackgroundInfluentialLi, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 100
Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
Zhang, A. Q., Hostetler, A., Chen, L. E., Mukkamala, V., Abraham, W. D., Padilla, L. T., Wolff, A. N., Maiorino, L., Backlund, C. M., Aung, A., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01048-8 · Cited by 100
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Kong, Y., Li, J., Zhao, X., Wu, Y., & Chen, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1519671 · Cited by 120
Yu, W.-L., & Hua, Z.-C. (2019) · Cancers · doi:10.3390/cancers11010047 · Cited by 89
Collinson-Pautz, M. R., Chang, W.-C., Lu, A., Khalil, M., Crisostomo, J., Lin, P.-Y., Mahendravada, A., Shinners, N. P., Brandt, M. E., Zhang, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0417-9 · Cited by 100
Stadtmauer, E. A., Faitg, T. H., Lowther, D. E., Badros, A. Z., Chagin, K., Dengel, K., Iyengar, M. K., Melchiori, L., Navenot, J., Norry, E., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000194 · Cited by 99
Kondo, T., Ando, M., Nagai, N., Tomisato, W., Srirat, T., Liu, B., Mise‐Omata, S., Ikeda, M., Chikuma, S., Nishimasu, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1196 · Cited by 99
Chou, C. K., & Turtle, C. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729735 · Cited by 96
“Due to an earlier median onset of CRS in studies of adults receiving axi-cel compared to tisagenlecleucel, we usually infuse the former in the hospital and the latter in the outpatient setting [2,6,7].”
BackgroundMethodInfluentialThe Future of Precision Oncology
Rulten, S. L., Grose, R. P., Gatz, S. A., Jones, J. L., & Cameron, A. J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612613 · Cited by 121
“New discoveries in disease biology, such as the correlation between genome instability and anti-tumor immune responses [63], the development of novel treatment modalities, such as CAR-T cell therapy [28], and improvements in technologies to couple precision companion diagnostics to targeted therapies [51], have also l…”
BackgroundGore, L., Locatelli, F., Zugmaier, G., Handgretinger, R., O'Brien, M. M., Bader, P., Bhojwani, D., Schlegel, P., Tuglus, C. A., & von Stackelberg, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0117-0 · Cited by 91
Self-citationAhmad, A., Shahab Uddin, M. S., & Steinhoff, M. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113906 · Cited by 94
“The overall remission rate was 81%, with at least three months of follow-up, and the remissions were observed to be durable, with the six-month relapse-free survival rate and overall survival rates being 80% and 90%, respectively [13].”
BackgroundCellular immunotherapies for cancer
Hayes, C. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02264-w · Cited by 100
“In addition to this, cellular drugs can persist in the body for months to years, whereas most conventional drugs are metabolised and excreted soon after administration, adding another layer to the complexity of the patient-drug interaction [18].”
BackgroundInfluentialDekker, L., Calkoen, F., Jiang, Y., Blok, H., Veldkamp, S. R., de Koning, C. C. H., Spoon, M., Admiraal, R., Hoogerbrugge, P. M., Vormoor, B. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006700 · Cited by 91
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
Seimetz, D., Heller, K., & Richter, J. (2019) · Cell Medicine · doi:10.1177/2155179018822781 · Cited by 90
Updates on CAR T‐cell therapy in B‐cell malignancies
Jacoby, E., Shahani, S. A., & Shah, N. N. (2019) · Immunological Reviews · doi:10.1111/imr.12774 · Cited by 86
Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy
Yi, F., Frazzette, N., Cruz, A. C., Klebanoff, C. A., & Siegel, R. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.05.004 · Cited by 92
“ACT has recently entered the standard of care for selected B-cell malignancies [69, 70] and has also shown promising efficacy in early phase clinical trials for patients with selected solid cancers [71–81].”
BackgroundBefriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy
Lindo, L., Wilkinson, L., & Hay, K. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618387 · Cited by 99
Lee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 99
Teh, B. W., Yeoh, D. K., Haeusler, G. M., Yannakou, C. K., Fleming, S. A., Lindsay, J., & Slavin, M. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15588 · Cited by 95
Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma
Meister, H., Look, T., Roth, P., Pascolo, S., Sahin, U., Lee, S., Hale, B. D., Snijder, B., Regli, L., Ravi, V. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4384 · Cited by 87
YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
Chen, Z., Zeng, C., Yang, L., Che, Y., Chen, M., Sau, L., Wang, B., Zhou, K., Chen, Y., Qing, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.007 · Cited by 101
Andorko, J. I., Russell, R. M., Schnepp, B. C., Grubaugh, D., Mullen, K. F., Wakabayashi, A., Carrington, L. J., O’Malley, T. M., Kuri-Cervantes, L., Culp, T. D., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.036 · Cited by 102
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 90
“In clinical trials with CD19 CAR T-cells for treatment of B-cell malignancies, up to 25% of patients with complete remission relapsed with CD19 negative disease (2).”
BackgroundResultMonitoring CAR T‐cells using flow cytometry
Demaret, J., Varlet, P., Trauet, J., Beauvais, D., Grossemy, A., Hégo, F., Yakoub‐Agha, I., & Labalette, M. (2021) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21941 · Cited by 84
“…of high levels of cytokines; and (b) toxicities resulting from specific interactions between the CAR and its target antigen expressed by nonmalignant cells—termed on-target, off-tumor effects respectively (Bonifant, Jackson, Brentjens, & Curran, 2016; Maude et al., 2018; Turtle et al., 2016b).”
BackgroundPoint mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
Zhang, Z., Chen, X., Tian, Y., Li, F., Zhao, X., Liu, J., Yao, C., & Zhang, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001150 · Cited by 92
Self-citationEngineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 81
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
Qayed, M. D., McGuirk, J. P., Myers, G. D., Parameswaran, V., Waller, E. K., Holman, P., Rodrigues, M., Clough, L. F., & Willert, J. R. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.05.003 · Cited by 96
Self-citationAdvances and perspectives in phototherapy-based combination therapy for cancer treatment
Yi, J., Liu, L., Gao, W., Zeng, J., Chen, Y., Pang, E.-N., Lan, M., & Yu, C. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00483c · Cited by 94
Perica, K., Curran, K. J., Brentjens, R. J., & Giralt, S. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.02.018 · Cited by 93
Chakraborty, R., Sidana, S., Shah, G. L., Scordo, M., Hamilton, B. K., & Majhail, N. S. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.11.025 · Cited by 90
Bishop, M. R., Maziarz, R. T., Waller, E. K., Jaeger, U., Westin, J. R., McGuirk, J. P., Fleury, I., Holte, H., Borchmann, P., del Corral, C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000151 · Cited by 88
“Cytokine release syndrome (CRS) was graded using the University of Pennsylvania grading scale and was managed by a protocol-specific algorithm.(5,9,10) A retrospective analysis of CRS severity using the Lee grading scale(11) was also conducted.”
MethodOkusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 98
Pediatric Acute Myeloid Leukemia—Past, Present, and Future
Reinhardt, D., Antoniou, E., & Waack, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030504 · Cited by 89
“The successful cellular therapy approaches in B-cell lymphocytic leukemia/lymphomas raise high hopes for myeloid neoplasms [98].”
BackgroundMinson, A. G., Hamad, N., Cheah, C. Y., Tam, C. S. L., Blombery, P. A., Westerman, D., Ritchie, D., Morgan, H., Holzwart, N., Lade, S., et al. (2023) · Blood · doi:10.1182/blood.2023021306 · Cited by 94
Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity
Zheng, Y., Yao, Y., Ge, T., Ge, S., Jia, R., Song, X., & Zhuang, A. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02845-4 · Cited by 102
“Cytokine release syndrome occurs in up to 77% of patients with ALL treated with CD19 CAR-T cells [16].”
BackgroundPrecise genome-editing in human diseases: mechanisms, strategies and applications
Zheng, Y., Li, Y., Zhou, K., Li, T., VanDusen, N. J., & Hua, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01750-2 · Cited by 106
Hucks, G., & Rheingold, S. R. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0164-6 · Cited by 94
Timing of first-in-child trials of FDA-approved oncology drugs
Neel, D. V., Shulman, D. S., & DuBois, S. G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.02.011 · Cited by 87
Burt, R. J., Warcel, D., & Fielding, A. K. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1540828 · Cited by 91
“Furthermore CAR-T therapy is associated with significant toxicity with some trials reporting severe CRS rates of up to 77%(45) and significant neurotoxicity including fatal events.(45)”
BackgroundRecent Advances in Managing Acute Lymphoblastic Leukemia
DeAngelo, D. J., Jabbour, E. J., & Advani, A. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280175 · Cited by 99
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
Walti, C. S., Krantz, E. M., Maalouf, J., Boonyaratanakornkit, J. B., Keane-Candib, J., Joncas-Schronce, L., Stevens‐Ayers, T., Dasgupta, S., Taylor, J. J., Hirayama, A. V. V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146743 · Cited by 100
“(%) Any HCT Any autologous Any allogeneic 6 (23) 5 (19) 1 (4) 18 (64) 2 (7) 16 (57) 4 (100) 4 (100) 0 4 (57) 4 (57) 2 (29) 32 (49) 15 (23) 19 (29) Time between most recent HCT and CAR-T cell infusion, months —median (range) 14 (7–46) 24 (3–117) 41 (13–72) 48 (29–65) 26 (3–117)”
Influential
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.